Holen Sie sich die Stockscreener-App
143.26
8.07%
10.70
Schlusskurs vom Vortag:
$132.56
Offen:
$135.52
24-Stunden-Volumen:
877.43K
Relative Volume:
1.01
Marktkapitalisierung:
$6.40B
Einnahmen:
$156.12M
Nettoeinkommen (Verlust:
$-395.33M
KGV:
-13.81
EPS:
-10.3758
Netto-Cashflow:
$-292.33M
1W Leistung:
+12.90%
1M Leistung:
+77.83%
6M Leistung:
+160.52%
1J Leistung:
+121.32%
1-Tages-Spanne:
$134.45
$143.50
1-Wochen-Bereich:
$126.74
$151.46
52-Wochen-Spanne:
$41.50
$151.46
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
143.26 | 5.67B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Mizuho | Neutral |
| 2026-03-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | TD Cowen | Hold |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Alle ansehen
Grail Inc Aktie (GRAL) Neueste Nachrichten
A Cancer Test Has Investors Betting Big. But Will Insurers Pay? - WSJ
The Galleri MCD vote: What FDA asked its advisors to ignore - The Cancer Letter
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run. - Yahoo Finance
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail' - Investor's Business Daily
Is GRAIL (GRAL) Expensive Following PATHFINDER 2 Results And The FDA Panel Vote? - Simply Wall Street
GRAL Stock Rockets Higher As Traders Hunt Momentum - StocksToTrade
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL) - Seeking Alpha
Grail's stock jumps 55% after positive FDA advi... - Pluang
Grail stock price target raised to $150 by Canaccord on FDA outlook - Investing.com
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test - Oncology Nursing News
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 By Investing.com - Investing.com South Africa
Form 4 Grail Inc For: 26 September By Investing.com - Investing.com Australia
Grail CFO Aaron Freidin sells $382,679 in company stock By Investing.com - Investing.com South Africa
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 - Investing.com
FDA Advisory Panel Backs Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test - clpmag.com
Just a Flesh Wound: The Combative Quest for Cancer’s Holy Grail - Inside Precision Medicine
FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote - qz.com
FDA panel endorses Grail Galleri multi-cancer blood test - Yahoo
Mizuho raises Grail stock price target to $100 on FDA panel vote - Investing.com Canada
Mizuho raises Grail stock price target to $100 on FDA panel vote By Investing.com - Investing.com South Africa
Here's Why Grail Stock Surged 55% This Week - The Motley Fool
Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL) - theglobeandmail.com
GRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focus - Stocktwits
Grail multicancer detection test wins FDA advisers’ backing - BioPharma Dive
This Controversial Cancer Test Just Passed a Key FDA Vote. Here's Why It's Dividing Experts - inc.com
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued? - Yahoo Finance
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test - Investor's Business Daily
FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says - FOX 10 Phoenix
GRAL Stock Surges As Traders Target High-Momentum Breakout - timothysykes.com
GRAL Stock Rockets As Traders Chase Breakout Momentum - StocksToTrade
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool - Benzinga
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test - marketscreener.com
One blood test could screen you for 50 cancers. Here’s why it’s controversial. - The Washington Post
Grail stock hits all-time high at 119.09 USD - Investing.com
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply. - Barron's
Grail stock hits all-time high at 119.09 USD By Investing.com - Investing.com Canada
Canaccord reiterates Buy on Grail stock after FDA panel vote - Investing.com
GRAIL Surges As FDA Panel Backs Cancer Blood Test - TipRanks
What is next for Grail stock after surging on positive FDA comments? - Investing.com
FDA panel endorses first-of-a-kind cancer blood test from Grail - Daily Herald
Grail survives adcomm vote as it awaits FDA decision for cancer blood test - Fierce Biotech
FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test - allsci.com
Canaccord reiterates Buy on Grail stock after FDA panel vote By Investing.com - Investing.com Nigeria
Grail MCED Test is Safe, Effective, Experts Tell FDA, While Questioning ‘Early Detection’ Claim - GenomeWeb
FDA panel endorses GRAIL’s multi-cancer early detection test - yahoo.com
Premarket movers: Stitch Fix tumbles, Grail surges - Investing.com
Why is Grail stock surging today? - Investing.com
FDA panel backs Galleri blood test that screens for more than 50 cancers - Straight Arrow
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Grail Inc-Aktie (GRAL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ofman Joshua J. | Chief Executive Officer |
Sep 21 '26 |
Option Exercise |
14.00 |
26,452 |
370,328 |
423,723 |
| Ofman Joshua J. | Chief Executive Officer |
Sep 21 '26 |
Sale |
97.74 |
61,452 |
6,006,378 |
362,271 |
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):